Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when WHWK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsWhitehawk Therapeutics reports Q1 2026 financial results
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
medium
Company announced first quarter 2026 financial results via press release on May 7, 2026. Specific revenue, earnings, and other financial metrics are not disclosed in the 8-K filing itself, only referenced in attached exhibit.
Item 2.02 verify on EDGAR → -
medium
Press release dated May 7, 2026 attached as Exhibit 99.1 contains the actual financial details, but is not included in the main filing body.
Exhibit 99.1 view on EDGAR →
Summary
Whitehawk Therapeutics filed an 8-K to announce its first quarter 2026 financial results through a press release dated May 7, 2026. This is a routine quarterly earnings disclosure required for public companies. However, the 8-K filing itself does not contain the actual financial figures—revenue, net income, cash position, or other key metrics—which are only available in the attached press release exhibit.
Retail investors should review the full press release (Exhibit 99.1) to understand the company's financial performance for the quarter ended March 31, 2026. Key items to watch include whether the company met analyst expectations, any updates on clinical trial progress or pipeline developments, and management's commentary on cash runway and funding needs. As a therapeutic development company, quarterly burn rate and cash position are particularly important metrics to monitor.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 7, 2026, Whitehawk Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K filing itself does not contain the actual financial figures, only references the press release as Exhibit 99.1. Without access to the exhibit, specific revenue, earnings, or other financial metrics cannot be determined from this filing.
Event · Item 9.01 — Financial Statements and Exhibits
Whitehawk Therapeutics filed an 8-K attaching a press release dated May 7, 2026; no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
Exhibit Number | Description | 99.1 | Press Release, dated May 7, 2026
The company attached a press release dated May 7, 2026 as Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature of the disclosure is unknown from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify